Compare
International Stem Cell Corp vs BioAge Labs, Inc. vs Precigen, Inc. vs Janux Therapeutics, Inc.
| Latest fiscal year | International Stem Cell Corp ISCO | BioAge Labs, Inc. BIOA | Precigen, Inc. PGEN | Janux Therapeutics, Inc. JANX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $9.10M | $8.99M | $9.68M | $10.00M |
| Revenue growth (YoY) | +0.2% | n/a | +146.7% | -5.6% |
| Gross margin | 55.7% (computed) | n/a | n/a | n/a |
| Operating margin | -2.9% | n/m | n/m | n/m |
| Net margin | -4.6% | -896.1% | n/m | n/m |
| Net income | -$418.0K | -$80.61M | -$250.64M | -$113.62M |
| EPS (Diluted) | -$0.05 | -$2.24 | -$1.37 | -$1.83 |
| Operating cash flow | $8.0K | -$81.63M | -$87.83M | -$82.23M |
| Free cash flow | -$35.0K | -$82.35M | -$89.83M | -$83.28M |
| Cash & equivalents | n/a | $188.89M | $30.23M | $52.33M |
| Total assets | $4.82M | $294.89M | $155.50M | $1.00B |
| Total liabilities | $4.58M | $22.84M | $134.59M | $44.74M |
| Shareholders' equity | -$4.06M | $272.05M | $20.91M | $956.82M |
| Return on year-end equity | n/a | -29.6% | n/m | -11.9% |
| Shares outstanding | 8.00M | 37.39M | 353.91M | 60.38M |
Revenue, most recent five fiscal years
| Fiscal year | International Stem Cell Corp | BioAge Labs, Inc. | Precigen, Inc. | Janux Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $9.10M Ended 2025-12-31 | $8.99M Ended 2025-12-31 | $9.68M Ended 2025-12-31 | $10.00M Ended 2025-12-31 |
| 1 year earlier | $9.09M Ended 2024-12-31 | $0 Ended 2024-12-31 | $3.92M Ended 2024-12-31 | $10.59M Ended 2024-12-31 |
| 2 years earlier | $7.79M Ended 2023-12-31 | n/a | $6.22M Ended 2023-12-31 | $8.08M Ended 2023-12-31 |
| 3 years earlier | $8.18M Ended 2022-12-31 | n/a | $26.91M Ended 2022-12-31 | $8.61M Ended 2022-12-31 |
| 4 years earlier | $7.18M Ended 2021-12-31 | n/a | $14.27M Ended 2021-12-31 | $3.64M Ended 2021-12-31 |